Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathurin Fumery

Showing results (151-160 of 254) with videos related to

Pageof 26
Sort By:
International Journal of Molecular Sciences|February 17, 2019
A Novel Rare Missense Variation of the <i>NOD2</i> Gene: Evidencesof Implication in Crohn's DiseaseSara Frade-Proud'Hon-Clerc, Thomas Smol, Frédéric Frenois, et al.
United European Gastroenterology Journal|May 5, 2021
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseAnthony Buisson, Stéphane Nancey, Luc Manlay, et al.
Alimentary Pharmacology & Therapeutics|August 21, 2018
Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort studyClaire Auzolle, Stephane Nancey, My-Linh Tran-Minh, et al.
Journal of Crohn'S & Colitis|June 30, 2022
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case SeriesBrigida Barberio, Edoardo Savarino, Bram Verstockt, et al.
Gut|December 10, 2015
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohortCorinne Gower-Rousseau, Hélène Sarter, Guillaume Savoye, et al.
Endoscopy International Open|September 11, 2025
Characterization of biomechanical risk factors during endoscopic submucosal dissection: Ergonomic pilot studyClara Yzet, Léa Leroy, Sylvain Chamot, et al.
The American Journal of Gastroenterology|July 4, 2020
Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's DiseaseNassim Hammoudi, Claire Auzolle, My-Linh Tran Minh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2018
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational studyLieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2026
One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID StudyNicolas Richard, Philippe Seksik, Romain Altwegg, et al.
Alimentary Pharmacology & Therapeutics|March 24, 2020
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort studyMarianne Hupé, Pauline Rivière, Stephane Nancey, et al.
Pageof 26

Showing results (151-160 of 254) with videos related to

Sort By:
Pageof 26
International Journal of Molecular Sciences|February 17, 2019
A Novel Rare Missense Variation of the <i>NOD2</i> Gene: Evidencesof Implication in Crohn's DiseaseSara Frade-Proud'Hon-Clerc, Thomas Smol, Frédéric Frenois, et al.
United European Gastroenterology Journal|May 5, 2021
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's diseaseAnthony Buisson, Stéphane Nancey, Luc Manlay, et al.
Alimentary Pharmacology & Therapeutics|August 21, 2018
Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort studyClaire Auzolle, Stephane Nancey, My-Linh Tran-Minh, et al.
Journal of Crohn'S & Colitis|June 30, 2022
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case SeriesBrigida Barberio, Edoardo Savarino, Bram Verstockt, et al.
Gut|December 10, 2015
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohortCorinne Gower-Rousseau, Hélène Sarter, Guillaume Savoye, et al.
Endoscopy International Open|September 11, 2025
Characterization of biomechanical risk factors during endoscopic submucosal dissection: Ergonomic pilot studyClara Yzet, Léa Leroy, Sylvain Chamot, et al.
The American Journal of Gastroenterology|July 4, 2020
Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's DiseaseNassim Hammoudi, Claire Auzolle, My-Linh Tran Minh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2018
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational studyLieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, et al.
Alimentary Pharmacology & Therapeutics|April 27, 2026
One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID StudyNicolas Richard, Philippe Seksik, Romain Altwegg, et al.
Alimentary Pharmacology & Therapeutics|March 24, 2020
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort studyMarianne Hupé, Pauline Rivière, Stephane Nancey, et al.
Pageof 26